BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 26, 2011
View Archived Issues
Phase III briakinumab data analyzed
Read More
Scientists at Astellas Pharma synthesize novel plasma kallikrein inhibitors
Read More
Phase II studies assess NGR-hTNF in lung and ovarian cancer
Read More
Novel TRPV4 antagonists prepared by researchers at GlaxoSmithKline
Read More
Phase III trial of cabozantinib meets primary endpoint
Read More
RetroSense Therapeutics licenses gene therapy from Wayne State University
Read More
EMA begins new review of Protelos and Osseor
Read More
Qutenza shows efficacy in HIV-associated neuropathy
Read More
New data presented from CARE-MS trials of alemtuzumab
Read More
Novel omega-3 MUFAs show oncolytic potential
Read More
Precision Antibody receives FDA contract to develop potency assays for influenza vaccine
Read More
TiGenix moves into randomized recruitment stage in phase Ia/IIb Cx-611 study
Read More
Merck Frosst discloses new HIV reverse transcriptase inhibitors
Read More
California Stem Cell acquires stem cell therapy program for metastatic melanoma
Read More
Basilea finishes multiple-ascending-dose study of antibiotic BAL-30072
Read More
Italian researchers prepare novel TRPV1 antagonists
Read More
New glucagon receptor antagonists designed by Merck & Co.
Read More
CDC advisory committee recommends Merck & Co.'s HPV vaccine for boys and young men
Read More
Lilly withdraws Xigris worldwide following PROWESS-SHOCK study
Read More
Bayer's phase III CORRECT trial meets primary endpoint
Read More
Elusys initiates new human safety study of anthrax treatment candidate
Read More
FDA provides update on safety review of Chantix
Read More
FDA grants IND clearance for phase II trial of Aeterna Zentaris' AEZS-108 in breast cancer
Read More
Seattle Genetics starts new Adcetris trial in nonlymphoma malignancies
Read More
DelMar Pharmaceuticals commences phase I/II trial of VAL-083
Read More